{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=31", "query": { "condition": "Lymphoma (Hodgkin's and Non-Hodgkin's)", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 881, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T02:47:43.616Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00807495", "title": "Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "Mantle Cell Lymphoma", "Burkitt's Lymphoma", "T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma", "Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2009-02-10", "completion_date": "2013-02-13", "has_results": true, "last_update_posted_date": "2018-03-27", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 1, "location_summary": "Mount Holly, New Jersey", "locations": [ { "city": "Mount Holly", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00807495" }, { "nct_id": "NCT00073957", "title": "Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "liposomal cytarabine", "type": "DRUG" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2003-12", "completion_date": "2012-01-01", "has_results": true, "last_update_posted_date": "2018-01-23", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Burlington, Vermont", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073957" }, { "nct_id": "NCT01938001", "title": "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2013-11-21", "completion_date": "2022-01-26", "has_results": true, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 35, "location_summary": "Mobile, Alabama • Glendale, Arizona • Escondido, California + 31 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01938001" }, { "nct_id": "NCT00396331", "title": "AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autologous Stem Cell Transplantation" ], "interventions": [ { "name": "G-CSF plus plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 100, "start_date": "2005-10", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2014-03-13", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 8, "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00396331" }, { "nct_id": "NCT02581631", "title": "An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Disease" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 145, "start_date": "2016-02-11", "completion_date": "2022-02-07", "has_results": true, "last_update_posted_date": "2023-03-07", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Miami, Florida • Tampa, Florida + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02581631" }, { "nct_id": "NCT00006252", "title": "Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "PBSC", "type": "BIOLOGICAL" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Donor lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Cancer and Leukemia Group B", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "69 Years", "sex": "ALL", "summary": "Up to 69 Years" }, "enrollment_count": 47, "start_date": "2001-02", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2016-07-18", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 19, "location_summary": "La Jolla, California • San Diego, California • San Francisco, California + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006252" }, { "nct_id": "NCT01244906", "title": "Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 26, "start_date": "2010-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2015-05-01", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01244906" }, { "nct_id": "NCT00048555", "title": "Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "IDEC-114", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2002-11", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2013-09-16", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048555" }, { "nct_id": "NCT02553447", "title": "Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma", "Untreated Chronic Lymphocytic Leukemia", "Vitamin D Deficiency" ], "interventions": [ { "name": "Cholecalciferol", "type": "DIETARY_SUPPLEMENT" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 197, "start_date": "2015-10-19", "completion_date": "2025-04-12", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02553447" }, { "nct_id": "NCT00244985", "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 42, "start_date": "2005-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-10-17T02:47:43.616Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244985" } ] }